Phycocyanin is a pigment-protein complex derived from cyanobacteria such as Spirulina. Its use in supporting or treating Alzheimer's Disease (AD) is based on emerging scientific research rather than traditional medicine. Several preclinical studies have investigated phycocyanin’s neuroprotective properties, mainly due to its potent antioxidant and anti-inflammatory effects. Oxidative stress and inflammation are significant contributors to the pathogenesis of Alzheimer's Disease, and phycocyanin has shown the ability to reduce oxidative damage and inhibit pro-inflammatory cytokines in cellular and animal models.

For example, studies in rodent models indicate that phycocyanin administration can improve cognitive function, decrease beta-amyloid accumulation, and modulate oxidative stress markers in the brain. However, these findings are primarily limited to laboratory and animal studies. There is currently a lack of robust clinical trials in humans to confirm these effects or establish therapeutic efficacy for Alzheimer's Disease. No major medical guidelines recommend phycocyanin as a treatment for AD.

In summary, while there is some scientific basis from preclinical research supporting the potential of phycocyanin for neuroprotection in Alzheimer's Disease, the overall evidence remains preliminary. Its use for this condition is not well-established in clinical practice, and more research is necessary before phycocyanin can be recommended as a therapy for Alzheimer's Disease.